Evidence map›Paper›PMID 36540116›Full record

ReviewNanoscale advances2022

Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease.

Obaydah Abd Alkader Alabrahim, Hassan Mohamed El-Said Azzazy

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanoscale advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Improved antimicrobial activities ofNanoscale advances · 2024
    Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Obaydah Abd Alkader AlabrahimGraduate Nanotechnology Program, School of Sciences & Engineering, The American University in Cairo 11835 New Cairo Egypt obaydah.alabrahim@aucegypt.edu.ORCID https://orcid.org/0000-0003-0906-7597
Hassan Mohamed El-Said AzzazyDepartment of Chemistry, School of Sciences & Engineering, The American University in Cairo AUC Avenue, P. O. Box 74 New Cairo 11835 Egypt hazzazy@aucegypt.edu.ORCID https://orcid.org/0000-0003-2047-4222
American University in Cairo · EGLeibniz Institute of Photonic Technology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the world's population ages, the incidence of Parkinson's disease (PD), the second most common neurological ailment, keeps increasing. It is estimated that 1% of the global population over the age of 60 has the disease. The continuous loss of dopaminergic neurons and the concomitant brain depletion of dopamine levels represent the hallmarks of PD. As a result, current PD therapies primarily target dopamine or its precursor (levodopa). Therapeutic approaches that aim to provide an exogenous source of levodopa or dopamine are hindered by their poor bioavailability and the blood-brain barrier. Nevertheless, the fabrication of many polymeric nanoparticles has been exploited to deliver several drugs inside the brain. In addition to a brief introduction of PD and its current therapeutic approaches, this review covers novel polymeric nanoparticulate drug delivery systems exploited lately for dopamine and levodopa replacement in PD.

Identifiers

PMID36540116
PMCPMC9724695
OpenAlexW4312095123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.